In plain words
One trial, described in a 2012 review, found that rhodiola lowered CRP, a blood marker of inflammation, five hours after exhausting exercise. A marathon trial and a smaller four-week study found no difference from placebo in inflammation markers.
The short answer
Two of the three studies that measured inflammation found no difference from placebo. Shanely and colleagues (2013) gave 48 people rhodiola or placebo for 30 days before a marathon; CRP and cytokines rose in both groups alike. Parisi and colleagues (2010) followed 14 people for 4 weeks and found inflammatory markers unaffected; the ledger has no dose for either study. The third, a trial described in Ishaque and colleagues' 2012 systematic review, found lower CRP 5 hours after exhausting exercise; the ledger has no n, dose or duration for it. Certainty is very low: the studies are few and small, and the one positive result reaches us second-hand.
Where the evidence sits
CRP lower with rhodiola
No difference from placebo
■ measured by the source's own study · ◪ pooled analysis, may overlap studies counted here · □ reported, reviewed or argued, no new data
Who says what
| Source | Finding | Design | People | Dose and length | Funding and independence |
|---|---|---|---|---|---|
| Shanely et al., 2013 | CRP and cytokines rose after the marathon, no difference from placebo | Randomized trial with placebo group | 48 | Not in ledger; 30 days | Not in ledger |
| Parisi et al., 2010 | Inflammatory markers unaffected | Small study compared with placebo | 14 | Not in ledger; 4 weeks | Not in ledger |
| Ishaque et al., 2012 | CRP lower at 5 hours; creatine kinase not lower | Systematic review describing an included randomized trial | Not in ledger | Not in ledger | Not in ledger |
| Skarpanska-Stejnborn et al., 2009 | Related outcome: antioxidant capacity higher, oxidative damage unchanged | Randomized, double-blinded trial | 22 rowers | 100 mg twice a day for 4 weeks | Not in ledger |
CRP and cytokines rose after the marathon, no difference from placebo
Inflammatory markers unaffected
CRP lower at 5 hours; creatine kinase not lower
Related outcome: antioxidant capacity higher, oxidative damage unchanged
What happened to CRP after a marathon?
Shanely and colleagues (2013) randomized 48 people to rhodiola or placebo for 30 days, then measured blood markers around a marathon. The ledger has no dose for this trial. Inflammation rose in everyone:
C-reactive protein (CRP), and eHSP72 all increased post-marathon (all p<0.001), with no group differences over time (all p>0.300)
Which trial found lower CRP?
Ishaque and colleagues' 2012 systematic review of rhodiola for fatigue describes one included trial that took blood after an exhausting exercise test. The review reports that CRP was lower with rhodiola, while creatine kinase, a marker of muscle damage, was not:
Findings indicate that R. rosea significantly lowered CRP levels at 5 hours
The ledger holds this result only as the review reports it, with no n, dose or duration.
Did a smaller study see any change?
Parisi and colleagues (2010) compared rhodiola with placebo in 14 people over 4 weeks, measuring antioxidant and inflammation markers in blood. The ledger has no dose for this study:
Blood antioxidant status and inflammatory parameters resulted unaffected by Rhodiola Rosea supplementation.
What about the closely related oxidative stress markers?
Skarpanska-Stejnborn and colleagues (2009) gave 22 professional rowers 100 mg twice a day or placebo for 4 weeks. Total plasma antioxidant capacity ended higher in the rhodiola group (p = .0002), but the authors drew a limit:
supplementation with R. rosea increased antioxidant levels in the plasma of professional rowers but had no effect on oxidative damage induced by exhaustive exercise
The ledger has no inflammation markers for this trial, so it sits outside the count above.
Why the sources disagree
The positive CRP result comes through a review describing someone else's trial, while the two null results come from the researchers' own studies. The exercise differed: a laboratory exhaustion test in the reviewed trial, a full marathon in Shanely's. Blood was drawn at 5 hours in the reviewed trial; the ledger has no sampling times for Shanely's trial beyond "over time". Training status may differ between groups. The ledger has no dose for any of the three inflammation studies, and funding is not in the ledger for any of the four sources.
What would settle it
A placebo-controlled trial giving 600 mg a day for 30 days, with CRP and cytokines measured before, 5 hours after and 24 hours after the same exhausting laboratory test, in at least 100 trained adults, with CRP at 5 hours pre-registered as the main outcome. A matching result from a second research group would raise certainty.
How this page was made
The 4 sources are the studies in the Longevity Circle ledger that measured inflammation or closely related blood markers after rhodiola, drawn from a literature search of rhodiola trials and reviews on PubMed. Safety studies and studies on mood, fatigue and cognition were left out because they did not measure inflammation. Every claim was copied word for word from its source into the ledger and checked against the original text, and a person approved each one. "Contested" means independent studies point in both directions; certainty follows the GRADE levels used in medical reviews. Drafting was assisted by AI.
The ledger holds only 2 studies on this question.
Changelog: 23 Sep 2026, first version, 4 sources.
